encorafenib (Mektovi)
Jump to navigation
Jump to search
Introduction
FDA approved June 2018
Indications
- for use in combination with binimetinib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma
Dosage
- 50-75 mg PO
Capsules: 50 mg. 75 mg
Adverse effects
- palmoplantar erythrodysaesthesia syndrome
- myalgia
- arthralgia[3]
Mechanism of action
- BRAF inhibitor
More general terms
Component of
References
- ↑ RxNorm
- ↑ Wikipedia: Encorafenib https://en.wikipedia.org/wiki/Encorafenib
- ↑ 3.0 3.1 Dummer R, Ascierto PA, Gogas HJ et al Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29573941